Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Recent results from numerous large breast cancer clinical trials have established the value of targeting the cell surface receptor HER2 (erbB2) with multiple HER2-targeted agents. This comprises the use of combined antibodies (trastuzumab plus pertuzumab) as first line therapy in metastatic breast cancer, combined antibody and small molecule tyrosine kinase inhibitor (trastuzumab plus lapatinib) in early breast cancer and antibody-drug conjugate (trastuzumab-DM1) in resistant disease.
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi